Literature DB >> 9857225

Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer.

B Göhring1, H J Holzhausen, A Meye, H Heynemann, U Rebmann, J Langner, D Riemann.   

Abstract

The regulatory mechanisms responsible for malignant transformation, tumor progression and metastasis in renal cell cancer (RCC) are still unclear, but there is some evidence that biologically active peptides might have regulatory effects on the behavior of this malignancy. Tumor cells can change local concentrations of active peptides by modulating their cell-surface enzymes. Using immunohistochemistry and enzyme-histochemistry, the expression of various membrane peptidases was examined in RCC and adjacent noninvaded renal parenchyma (n = 44). We describe the down-regulation of neutral endopeptidase 24.11 (NEP) protein expression in RCC of the clear cell/chromophilic type when compared with renal parenchyma, and show for the first time the lack of enzyme activity of NEP in RCC. The strongest expression could be found for dipeptidyl peptidase IV (DPIV) which is only decreased in RCC of the chromophobe cell type and is even present in oncocytoma. Aminopeptidase N (APN) and aminopeptidase A (APA) show attenuated expression in up to one third of clear cell/ chromophilic RCC. Chromophobe RCC and oncocytomas do not express APN, APA, NEP and gamma-glutamyltranspeptidase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857225     DOI: 10.3892/ijmm.2.4.409

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

1.  Candidate biomarkers in exosome-like vesicles purified from rat and mouse urine samples.

Authors:  Javier Conde-Vancells; Eva Rodriguez-Suarez; Esperanza Gonzalez; Agustin Berisa; David Gil; Nieves Embade; Mikel Valle; Zigmund Luka; Felix Elortza; Conrad Wagner; Shelly C Lu; Jose M Mato; M Falcon-Perez
Journal:  Proteomics Clin Appl       Date:  2010-04       Impact factor: 3.494

2.  Submaxillary gland androgen-regulated protein 3A expression is an unfavorable risk factor for the survival of oropharyngeal squamous cell carcinoma patients after surgery.

Authors:  Jennifer Koffler; Dana Holzinger; Gustavo Acuña Sanhueza; Christa Flechtenmacher; Karim Zaoui; Bernd Lahrmann; Niels Grabe; Peter K Plinkert; Jochen Hess
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-05       Impact factor: 2.503

3.  CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.

Authors:  Duygu Gürel; Aydanur Kargı; Ilgın Karaman; Ahmet Onen; Mehtat Unlü
Journal:  Pathol Oncol Res       Date:  2011-06-18       Impact factor: 3.201

4.  Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.

Authors:  Nuray Erin; Tümay İpekçi; Bahar Akkaya; İrem Hicran Özbudak; Mehmet Baykara
Journal:  Cancer Microenviron       Date:  2016-10-19

5.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression.

Authors:  Hend Braham; Mounir Trimeche; Sonia Ziadi; Sarra Mestiri; Moncef Mokni; Khaled Amara; Mohamed Hachana; Badreddine Sriha; Sadok Korbi
Journal:  Virchows Arch       Date:  2006-05-04       Impact factor: 4.064

7.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

8.  The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?

Authors:  N N Nalivaeva; N D Belyaev; I A Zhuravin; A J Turner
Journal:  Int J Alzheimers Dis       Date:  2012-07-26

9.  Differential expression of CD10 in prostate cancer and its clinical implication.

Authors:  Marc A Dall'Era; Lawrence D True; Andrew F Siegel; Michael P Porter; Tracy M Sherertz; Alvin Y Liu
Journal:  BMC Urol       Date:  2007-03-02       Impact factor: 2.264

10.  Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis.

Authors:  F Laube; B Göhring; H Sann; I Willhardt
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.